Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RLMD |
---|---|---|
09:32 ET | 1035 | 3.84 |
09:36 ET | 300 | 3.8759 |
09:48 ET | 1000 | 3.855 |
09:50 ET | 312 | 3.84 |
09:54 ET | 200 | 3.83 |
10:17 ET | 100 | 3.84 |
10:26 ET | 4901 | 3.85 |
10:30 ET | 900 | 3.83 |
10:33 ET | 100 | 3.8 |
10:37 ET | 100 | 3.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Relmada Therapeutics Inc | 115.9M | -1.2x | --- |
Regulus Therapeutics Inc | 113.9M | -1.2x | --- |
Tevogen Bio Holdings Inc | 117.9M | -1,604.7x | --- |
X4 Pharmaceuticals Inc | 119.1M | -1.1x | --- |
Nuvectis Pharma Inc | 122.1M | -4.9x | --- |
Immunic Inc | 122.5M | -0.8x | --- |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $115.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.52 |
EPS | $-3.13 |
Book Value | $2.84 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.